Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary - Summary - MDSpire

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

  • By

  • Shruti K. Gohil

  • Taliser R. Avery

  • Ken Kleinman

  • Edward Septimus

  • Amarah Mauricio

  • Kenneth E. Sands

  • Neha Varma

  • Selsebil Sljivo

  • Kaleb Roemer

  • William S. Cooper

  • Russell E. Poland

  • Robert A. Weinstein

  • Samir M. Fakhry

  • Jeffrey Guy

  • Julia Moody

  • Micaela H. Coady

  • Kim N. Smith-Sells

  • Mary K. Hayden

  • David W. Kubiak

  • Chenette Burks

  • Richard Platt

  • Susan S. Huang

  • Meghan A. Baker

  • June 10, 2026

  • 0 min

Share

Objective:

To evaluate the association of a specific antibiotic stewardship intervention with clinicians’ antibiotic use for hospitalized cancer patients.

Key Findings:
  • The intervention significantly reduced the selection of extended-spectrum antibiotics in non–critically ill patients, demonstrating its effectiveness.
  • Patients with cancer were included in the analysis without exclusion, allowing for a thorough assessment of antibiotic use in this vulnerable population.
Interpretation:

The study highlights the potential for antibiotic stewardship interventions to optimize initial antibiotic selection in hospitalized cancer patients, addressing a critical gap in current practices.

Limitations:
  • The analysis was retrospective and may be subject to biases inherent in observational studies, which could affect the reliability of the findings.
  • The study did not evaluate long-term outcomes related to antibiotic use in cancer patients, limiting the understanding of the intervention's full impact.
Conclusion:

The findings suggest that antibiotic stewardship strategies can be effectively applied to hospitalized cancer patients to reduce unnecessary exposure to extended-spectrum antibiotics, potentially improving patient outcomes.

Original Source(s)

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

  • by Shruti K. Gohil, Taliser R. Avery, Ken Kleinman, Edward Septimus, Amarah Mauricio, Kenneth E. Sands, Neha Varma, Selsebil Sljivo, Kaleb Roemer, William S. Cooper, Russell E. Poland, Robert A. Weinstein, Samir M. Fakhry, Jeffrey Guy, Julia Moody, Micaela H. Coady, Kim N. Smith-Sells, Mary K. Hayden, David W. Kubiak, Chenette Burks, Richard Platt, Susan S. Huang, Meghan A. Baker

  • June 10, 2026

Related Content

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation

This Week’s CGT News: Promising Data for In Vivo CAR T

Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts

  • June 8, 2026

  • 6 min